# US 2019/0314285 A1 · Dosage forms comprising abiraterone acetate

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314285 A1
- Document ID: US20190314285A1
- Status: Published application
- Kind: A1
- Application number: 16/380,138
- Filed: 2019-04-10
- Published: 2019-10-17
- Earliest claimed: 2018-04-13
- Assignees: Janssen Pharmaceutica NV
- Applicants: Janssen Pharmaceutica NV
- Inventors: Jurgen Mensch; Urbain Alfons C. Delaet; Philip Erna H. Heyns; Claire Elisabeth Balmain
- Web page: https://patentgrep.com/patent/US20190314285A1

## CPC

- A61K 9/28: Dragees; Coated pills or tablets {, e.g. with film or compression coating (A61K9/2072 takes precedence, e.g. partially coated tablets A61K9/2072, coated multilayer tablets A61K9/2086, tablets with drug-coated core A61K9/209)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/284: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone}
- A61K 31/58: containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin (digitoxin {A61K31/7048})
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are solid oral dosage forms comprising about 500 mg of abiraterone acetate; and a film coating that is positioned on an outer surface of said dosage form, wherein the dosage forms are bioequivalent to 250 mg ZYTIGA® abiraterone acetate dosage forms when administered orally on an equivalent dose basis. Also disclosed are approved drug products comprising 500 mg abiraterone acetate, as are methods of treatment, of reducing pill burden, and of providing pharmaceutical regimen that is bioequivalent to 250 mg ZYTIGA® abiraterone acetate dosage forms when administered orally on an equivalent dose basis.

## Claims

### Claim 1

A solid oral dosage form comprising about 500 mg of abiratirone acetate and having a dissolution profile characterized by one or more of features (a)-(f):
(a) about 43% of said dosage form dissolves after five minutes;
(b) about 71% of said dosage form dissolves after 10 minutes;
(c) about 88% of said dosage form dissolves after 20 minutes;
(d) about 94% of said dosage form dissolves after 30 minutes;
(e) about 98% of said dosage form dissolves after 45 minutes; and,
(f) about 99% of said dosage form dissolves after 60 minutes,
when measured by the USP 2 Paddle method at 75 rpm in 900 mL of an aqueous solution comprising 56.5 mM phosphate buffer with 0.25% (w/v) sodium lauryl sulfate at pH 4.5 and a temperature of 37.0±0.5° C.

### Claim 2

A solid oral dosage form comprising about 500 mg of abiratirone acetate and having a dissolution profile characterized by one or more of features (a)-(f):
(a) about 31% of said dosage form dissolves after five minutes;
(b) about 65% of said dosage form dissolves after 10 minutes;
(c) about 94% of said dosage form dissolves after 20 minutes;
(d) about 98% of said dosage form dissolves after 30 minutes;
(e) about 99% of said dosage form dissolves after 45 minutes; and,
(f) about 99% of said dosage form dissolves after 60 minutes,
when measured by the USP 2 Paddle method at 75 rpm in 900 mL of an aqueous solution comprising 56.5 mM phosphate buffer with 0.25% (w/v) sodium lauryl sulfate at pH 4.5 and a temperature of 37.0±0.5° C.

### Claim 3

A solid oral dosage form comprising:
about 500 mg of abiraterone acetate; and
a film coating that is positioned on an outer surface of said dosage form,
wherein said dosage forms are bioequivalent, when administered orally on an equivalent dose basis, to 250 mg ZYTIGA® abiraterone acetate dosage forms.

### Claim 4 (depends on 1)

The dosage form according to claim 1 comprising about 30 to about 50 wt % of said abiraterone acetate.

### Claim 5 (depends on 4)

The dosage form according to claim 4 comprising about 35 to about 45 wt % of said abiraterone acetate.

### Claim 6 (depends on 5)

The dosage form according to claim 5 comprising about 35 wt % of said abiraterone acetate.

### Claim 7 (depends on 5)

The dosage form according to claim 5 comprising about 45 wt % of said abiraterone acetate.

### Claim 8 (depends on 1)

The dosage form according to claim 1 further comprising one or more of a diluent, a disintegrant, a binder, a surfactant, a glidant, or a lubricant.

### Claim 9 (depends on 2)

The dosage form according to claim 2 further comprising a diluent, a disintegrant, a binder, a surfactant, a glidant, and a lubricant.

### Claim 10 (depends on 8)

The dosage form according to claim 8 further comprising a diluent that is selected from lactose monohydrate, microcrystalline cellulose, and silicified microcrystalline cellulose.

### Claim 11 (depends on 8)

The dosage form according to claim 8 further comprising a disintegrant, wherein said disintegrant is croscarmellose sodium.

### Claim 12 (depends on 8)

The dosage form according to claim 8 further comprising a binder that is selected from povidone and hypromellose.

### Claim 13 (depends on 8)

The dosage form according to claim 8 further comprising a surfactant, wherein said surfactant is sodium lauryl sulfate.

### Claim 14 (depends on 8)

The dosage form according to claim 8 comprising lactose monohydrate, microcrystalline cellulose or silicified microcrystalline cellulose, croscarmellose sodium, povidone or hypromellose, sodium lauryl sulfate, colloidal silicon dioxide, and magnesium stearate.

### Claim 15 (depends on 14)

The dosage form according to claim 14 comprising about 22-28 wt % lactose monohydrate, about 16-17 wt % microcrystalline cellulose or about 18-20 wt % silicified microcrystalline cellulose, about 6-7 wt % croscarmellose sodium, about 4-6 wt % povidone or about 1-2 wt % hypromellose, about 4-6 wt % sodium lauryl sulfate, about 0.5-1.5 wt % colloidal silicon dioxide, and about 1-2 wt % magnesium stearate.

### Claim 16 (depends on 15)

The dosage form according to claim 15, wherein said dosage form comprises about 35 wt % abiraterone acetate, about 28 wt % lactose monohydrate, about 20 wt % silicified microcrystalline cellulose, about 6 wt % croscarmellose sodium, about 5 wt % povidone, about 1 wt % colloidal silicon dioxide, and about 1.5 wt % magnesium stearate, wherein the combination of each of said components in the dosage form equals 100 wt %.

### Claim 17 (depends on 15)

The dosage form according to claim 15, wherein said dosage form comprises about 45 wt % abiraterone acetate, about 23 wt % lactose monohydrate, about 17 wt % microcrystalline cellulose, about 6 wt % croscarmellose sodium, about 2 wt % hypromellose, about 1 wt % colloidal silicon dioxide, and about 1.5 wt % magnesium stearate, wherein the combination of each of said components in the dosage form equals 100 wt %.

### Claim 18 (depends on 1)

The dosage form according to claim 1, wherein two of said dosage forms administered orally at substantially the same time exhibit a Cmax of about 130 ng/mL.

### Claim 19 (depends on 1)

The dosage form according to claim 1, wherein two of said dosage forms administered orally at substantially the same time exhibit a Cmax of about 108 ng/mL.

### Claim 20 (depends on 1)

The dosage form according to claim 1, wherein two of said dosage forms administered orally at substantially the same time exhibit a tmax at about 2.0 hours.

### Claim 21 (depends on 1)

The dosage form according to claim 1, wherein two of said dosage forms administered orally at substantially the same time exhibit an area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast) of about 679 ng*h/mL.

### Claim 22 (depends on 1)

The dosage form according to claim 1, wherein two of said dosage forms administered orally at substantially the same time exhibit an area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast) of about 589 ng*h/mL.

### Claim 23 (depends on 1)

The dosage form according to claim 1, wherein two of said dosage forms administered orally at substantially the same time exhibit an area under the plasma concentration-time curve extrapolated to infinite time (AUC∞) of about 707 ng*h/mL.

### Claim 24 (depends on 1)

The dosage form according to claim 1, wherein two of said dosage forms administered orally at substantially the same time exhibit an area under the plasma concentration-time curve extrapolated to infinite time (AUC∞) of about 600 ng*h/mL.

### Claim 25 (depends on 1)

The dosage form according to claim 1, wherein two of said dosage forms administered orally at substantially the same time exhibit an apparent terminal elimination half-life (t1/2) of about 18.6 hours.

### Claim 26 (depends on 1)

The dosage form according to claim 1, wherein two of said dosage forms administered orally at substantially the same time exhibit an apparent terminal elimination half-life (t1/2) of about 18.1 hours.

### Claim 27 (depends on 1)

A method of reducing pill burden on a subject in need of an abiraterone acetate pharmaceutical regimen comprising orally administering to a subject two dosage forms according to claim 1 at substantially the same time.

### Claim 28 (depends on 27)

A method of treating a subject using an abiraterone acetate pharmaceutical regimen that is bioequivalent to 250 mg ZYTIGA® abiraterone acetate dosage forms when administered orally on an equivalent dose basis, comprising orally administering a dosage form according to claim 27.

### Claim 29 (depends on 1)

A method of treating a subject who has prostate cancer comprising orally administering to said subject a dosage form according to claim 1.

### Claim 30 (depends on 29)

The method according to claim 29 comprising orally administering to said subject two of said dosage forms at substantially the same time.

### Claim 31

A method of selling a drug product comprising abiraterone acetate, said method comprising selling such drug product, wherein a drug product label for a reference listed drug for such drug product includes instructions for treating non-metastatic castration resistant prostate cancer.

### Claim 32 (depends on 31)

The method of claim 31, wherein the drug product is an ANDA drug product, a supplemental New Drug Application drug product or a 505(b)(2) drug product.

### Claim 33

A method of offering for sale a drug product comprising abiraterone acetate, said method comprising offering for sale such drug product, wherein a drug product label for a reference listed drug for such drug product includes instructions for treating non-metastatic castration resistant prostate cancer.

### Claim 34 (depends on 33)

The method of claim 33, wherein the drug product is an ANDA drug product, a supplemental New Drug Application drug product or a 505(b)(2) drug product.

### Claim 35

A method of selling a drug product comprising abiraterone acetate, said method comprising selling such drug product, wherein the drug product label for a reference listed drug for such drug product comprises metastasis free survival data.

### Claim 36 (depends on 35)

The method of claim 35, wherein the metastasis free survival data for abiraterone acetate in combination with androgen deprivation therapy arm has a median of about 40.5 months.

### Claim 37

A method of offering for sale a drug product comprising abiraterone acetate, said method comprising offering for sale such drug product, wherein the drug product label for a reference listed drug for such drug product comprises metastasis free survival data.

### Claim 38 (depends on 37)

The method of claim 37, wherein the metastasis free survival data for abiraterone acetate in combination with androgen deprivation therapy arm has a median of about 40.5 months.

### Claim 39

An approved drug product comprising 500 mg abiraterone acetate.

### Claim 40 (depends on 39)

An approved drug product of claim 39, wherein the approved drug product is a NDA drug product, an ANDA drug product, a supplemental New Drug Application drug product, or a 505(b)(2) drug product.

### Claim 41 (depends on 39)

An approved drug product of claim 39, wherein a reference listed drug product for the approved drug product includes a drug product label.

### Claim 42 (depends on 41)

An approved drug product of claim 41, wherein the drug product label comprises metastasis free survival data.
